Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Factors contributing to retroviral integration have been intractable because past studies have not precisely located genomic sites of proviruses in sufficient numbers for significant analysis. In this study, 903 murine leukemia virus (MLV) and 379 human immunodeficiency virus–1 (HIV-1) integrations in the human genome were mapped. The data showed that MLV preferred integration near the start of transcriptional units (either upstream or downstream) whereas HIV-1 preferred integration anywhere in the transcriptional unit but not upstream of the transcriptional start. Defining different integration site preferences for retroviruses will have important ramifications for gene therapy and may aid in our understanding of the factors directing the integration process.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The well-understood integration preferences of HIV-1 for active transcription units72 and MLV for promoter/enhancer regions73–75 are in large part dictated via specific interactions of the respective IN proteins with chromatin-bound host factors.”
From Structure and function of retroviral integrase (2022) · cites this paper as [73]
In the citing paper
“Multiple studies now indicate that gammaretroviral vectors such as the vectors used in the two SCID-X1 trials preferentially integrate into the 5′ end of genes, near the transcription start sites[47].”
From Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia (2009) · cites this paper as [47]
In the citing paper
“Finally, the preferred sequences of the genome for integration are different from the γ-RVV, with LVV preferentially integrating in genes and introns away for transcriptional start sites preferred by γ-RVV.20”
From Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy (2025) · cites this paper as [20]
Citations
Cites
CpG-rich islands and the function of DNA methylation
Bird, A. P. (1986) · Nature · doi:10.1038/321209a0 · Cited by 3,777
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy
Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., Bouneaud, C., Hue, C., De Villartay, J.-P., Thrasher, A. J., Wulffraat, N., Sorensen, R., Dupuis-Girod, S., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012616 · Cited by 1,058
CpG islands as gene markers in the human genome
Larsen, F., Gundersen, G., Lopez, R., & Prydz, H. (1992) · Genomics · doi:10.1016/0888-7543(92)90024-m · Cited by 922
Pryciak, P. M., & Varmus, H. E. (1992) · Cell · doi:10.1016/0092-8674(92)90289-o · Cited by 273
Introducing RefSeq and LocusLink: curated human genome resources at the NCBI
Pruitt, K. D., Katz, K. S., Sicotte, H., & Maglott, D. R. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(99)01882-x · Cited by 241
Check, E. (2002) · Nature · doi:10.1038/420116a · Cited by 238
Pruss, D., Bushman, F. D., & Wolffe, A. P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.5913 · Cited by 236
Transcriptionally active genome regions are preferred targets for retrovirus integration
Scherdin, U., Rhodes, K., & Breindl, M. (1990) · Journal of Virology · doi:10.1128/jvi.64.2.907-912.1990 · Cited by 210
Research works printed but not linked: 2
- National Center for Biotechnology Information Reference Sequence Project (RefSeq) www.ncbi.nlm.nih.gov/RefSeq/.
- The database is available online at www.ncbi.nlm.nih.gov/geo/.
Cited by
Items 801–900 of 1,000
Thérapie génique du déficit immunitaire combiné sévère lié à l’X
Fischer, A., Hacein‐Bey‐Abina, S., & Cavazzana, M. (2004) · médecine/sciences · doi:10.1051/medsci/2004201115 · Cited by 14
“que ces provirus s’intègrent préférentiellement au sein de gènes «actifs», principalement à proximité du promoteur [7].”
Farruggio, A. P., Bhakta, M. S., du Bois, H., Ma, J., & Calos, M. P. (2017) · Biotechnology Journal · doi:10.1002/biot.201600477 · Cited by 14
Transforming science: cancer gene identification
Collier, L. S., & Largaespada, D. A. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2005.11.001 · Cited by 14
“In addition to limited tissue-type access, the proviruses of slow-transforming retroviruses demonstrate marked preference for inserting near the 50 end of actively transcribed genes in the host genome [24].”
BackgroundWeiser, K. C., Liu, B., Hansen, G. M., Skapura, D. G., Hentges, K. E., Yarlagadda, S. P., Morse, H. C., & Justice, M. J. (2007) · Mammalian Genome · doi:10.1007/s00335-007-9060-2 · Cited by 14
“Estimation of false-positive rate and degree of saturation MuLV insertions can occur in any chromosome in a sequence-independent manner, but MuLV exhibits a slight preference for insertions near transcriptional start sites and CpG islands (Lewinski et al. 2006; reviewed in Wu et al. 2003).”
BackgroundMethodKim, S., Kim, Y., Liang, T., Sinsheimer, J. S., & Chow, S. A. (2006) · Journal of Virology · doi:10.1128/jvi.01737-06 · Cited by 17
“In contrast to the random control, the distribution of NL-Mme integration sites determined by the conventional assay was significantly favored in transcription units (60.1%, P 0.0001) and Alu elements (16.4%, P 0.0035) and disfavored in LTR-E (5.3%, P 0.0193) and the L1 member of the LINE class (11.8%, P 0.0093) (Fig.”
BackgroundMethodResultInfluentialAker, M., Tubb, J., Miller, D. G., Stamatoyannopoulos, G., & Emery, D. W. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.02.016 · Cited by 14
Singh, S., Khan, I., Khim, S., Seymour, B., Sommer, K., Wielgosz, M., Norgaard, Z., Kiem, H.-P., Adair, J., Liggitt, D., et al. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.11.001 · Cited by 13
CHD1 and CHD2 are positive regulators of HIV-1 gene expression
Rodgers, M. J., Banks, D. J., Bradley, K. A., & Young, J. A. T. (2014) · Virology Journal · doi:10.1186/1743-422x-11-180 · Cited by 13
“Since MLV DNA is preferentially integrated close to cellular gene transcription start sites [31], this approach can result in conditional silencing of cellular gene expression.”
BackgroundCell-and Gene-based Therapeutic Approaches for Neurological Deficits in Mucopolysaccharidoses
Pan, D. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111795542679 · Cited by 14
“In addition, integration site mapping studies have revealed that MLV preferentially integrates in and around gene promoters (±1 kb from CpG islands); whereas, HIV-1 integrates mostly within transcriptional units [136, 137].”
Genetic Labeling of Neuronal Subsets through Enhancer Trapping in Mice
Kelsch, W., Stolfi, A., & Lois, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038593 · Cited by 13
“In order to clone pieces of genomic DNA flanking the insertion site of the probe we performed ligation-mediated PCR (LM-PCR) from the genomic DNA of transgenic mice carrying single copies [30].”
MethodPapapetrou, E. P., & Sadelain, M. (2011) · Nature Protocols · doi:10.1038/nprot.2011.362 · Cited by 15
“Moreover, the semirandom pattern of retroviral integration and the high propensity of integration near or inside active genes and promoter region”
BackgroundChimeric HIV‐1 and HIV‐2 lentiviral vectors with added safety insurance
Sachdeva, G., D’Costa, J., Cho, J. E., Kachapati, K., Choudhry, V., & Arya, S. K. (2006) · Journal of Medical Virology · doi:10.1002/jmv.20767 · Cited by 13
“While both the conventional retroviruses and lentiviruses have the propensity to integrate into the active or expressed genes, the conventional retroviruses prefer integration sites in or near the promoters, while lentiviruses prefer to integrate into the body of the gene [Wu et al., 2003; Mitchell et al., 2004].”
BackgroundHost Cell Factors and HIV-1 Integration
Engelman, A. (2007) · Future HIV Therapy · doi:10.2217/17469600.1.4.415 · Cited by 14
“Genes and transcriptional activity only marginally influence MoMLV, although fully one-fourth of all integrations occur within 5 kb of transcription start sites [19–21].”
BackgroundMethodology and software to detect viral integration site hot-spots
Presson, A. P., Kim, N., Xiaofei, Y., Chen, I. S. Y., & Kim, S. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-367 · Cited by 13
“As a result, it is important to study genes and DNA features located within or near vector integration site (VIS) hot-spots to gain insight into the mechanism of vector integration and predict potential long-term toxicity of gene therapy vectors [13-16].”
BackgroundAugustyniak, J., Zychowicz, M., Podobińska, M., Bárta, T., & Bużańska, L. (2014) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2014-2000 · Cited by 14
“However, upon transduction, retroviral vectors are randomly integrated into the host genome, thus significantly increasing the risk of insertional mutagenesis and cancer (Schroder et al. 2002, Wu et al. 2003, Bushman et al. 2005, Okita et al. 2008).”
BackgroundHuman Polycomb groupEED protein negatively affects HIV-1 assembly and release
Rakotobe, D., Tardy, J.-C., André, P., Hong, S. S., Darlix, J., & Boulanger, P. A. (2007) · Retrovirology · doi:10.1186/1742-4690-4-37 · Cited by 13
“They were also consistent with the finding that HIV-1 preferentially integrates into transcriptionally active regions of the host genome [19-22].”
ResultRavin, S. S. D., & Malech, H. L. (2008) · Immunologic Research · doi:10.1007/s12026-008-8073-6 · Cited by 13
“While MLV’s preferred integration is near the start of transcriptional units (either 50 or 30), lentiviral vectors favor intragenic sites with a distribution along the entire length of the gene [83].”
BackgroundTolerance induction by lentiviral gene therapy with a nonmyeloablative regimen
Mitsuhashi, N., Fischer‐Lougheed, J., Shulkin, I., Kleihauer, A., Kohn, D. B., Weinberg, K. I., Starnes, V. A., & Kearns‐Jonker, M. (2005) · Blood · doi:10.1182/blood-2005-03-1172 · Cited by 13
Viral Determinants of Integration Site Preferences of Simian Immunodeficiency Virus-Based Vectors
Monse, H., Laufs, S., Kuate, S., Zeller, W. J., Früehauf, S., & Überla, K. (2006) · Journal of Virology · doi:10.1128/jvi.00373-06 · Cited by 16
“Subsequently, murine leukemia virus (MLV), and to a limited extent avian leukosis virus, was also found to preferentially integrate into transcriptional units (17, 21, 23, 30).”
BackgroundMethodUnsinger, J., Lindenmaier, W., May, T., Häuser, H., & Wirth, D. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.05.067 · Cited by 13
The evolution of transposons in Schizosaccharomyces pombe
Kelly, F. D., & Levin, H. L. (2005) · Cytogenetic and Genome Research · doi:10.1159/000084990 · Cited by 13
“Consistent with this reasoning is the recent finding that HIV-1 preferentially integrates into RNA polymerase II transcription units (Schroder et al., 2002; Wu et al., 2003).”
BackgroundMoreau-Gachelin, F. (2006) · PubMed · Cited by 18
Virus–Host Interactions in Retrovirus Integration
Engelman, A. N., & Maertens, G. N. (2018) · Retrovirus-Cell Interactions · doi:10.1016/b978-0-12-811185-7.00004-2 · Cited by 12
Lentivirus technologies for modulation of the immune system
Houghton, B. C., Booth, C., & Thrasher, A. J. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.08.007 · Cited by 12
Retrovirus-based vectors for transient and permanent cell modification
Schott, J. W., Hoffmann, D., & Schambach, A. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.09.004 · Cited by 13
Foamy virus as a gene transfer vector to the central nervous system
Caprariello, A. V., Miller, R. H., & Selkirk, S. M. (2008) · Gene Therapy · doi:10.1038/gt.2008.171 · Cited by 12
Embryonic Stem Cells as a Platform for Analyzing Neural Gene Transcription
Zhang, X., Horrell, S. A., Delaney, D., & Gottlieb, D. I. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0902 · Cited by 14
Mayasari, N. I., Mukougawa, K., Shigeoka, T., Kawakami, K., Kawaichi, M., & Ishida, Y. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks262 · Cited by 12
“We found that the conditional retrovirus vector tends to be preferentially inserted into the promoter regions (located 50 to the first exons) or into the first introns of trapped genes as has already been shown for a number of MMLV vectors (Figure 4D, beige bars; Supplementary Figure S3) (33).”
BackgroundSalamango, D. J., Evans, D. A. P., Baluyot, M. F., Furlong, J. N., & Johnson, M. C. (2013) · Journal of Virology · doi:10.1128/jvi.02524-13 · Cited by 12
Yang, S., Karne, N. K., Goff, S. L., Black, M. A., Xu, H., Bischof, D., Cornetta, K. G., Rosenberg, S. A., Morgan, R. A., & Feldman, S. A. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.199 · Cited by 13
“On the basis of current data, it appears that LVVs have a more ‘‘random’’ integration pattern and do not target the enhancers located at the 5¢ end of transcriptionally active genes (Wu et al., 2003).”
Soto, M. J., Peña, Á., & Vallejo, F. G. (2010) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2010.0182 · Cited by 12
Genomic Amplification of an Endogenous Retrovirus in Zebrafish T-Cell Malignancies
Frazer, J. K., Batchelor, L. A., Bradley, D. F., Brown, K. H., Dobrinski, K. P., Lee, C., & Trede, N. S. (2012) · Advances in Hematology · doi:10.1155/2012/627920 · Cited by 12
“MLV-related retroviruses are known to be oncogenic by insertional mutagenesis [18], and the determinants governing their preferred integration sites have been the subject of intense scientific scrutiny [19–21].”
Silencing and Variegation of Gammaretrovirus and Lentivirus Vectors
Ellis, J. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.ft-126 · Cited by 12
Genetic strategies for the treatment of sickle cell anaemia
Mansilla‐Soto, J., Rivière, I., & Sadelain, M. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08773.x · Cited by 12
“The integration pattern of retroviruses is semi-random and biased towards genes and their vicinity in approximately two-thirds of all integration events (Schroder et al, 2002; Wu et al, 2003; Mitchell et al, 2004; De Palma et al, 2005; Trobridge et al, 2006).”
BackgroundViral Vaccines for Cancer Immunotherapy
Eisenberger, A. B., Elliott, B., & Kaufman, H. L. (2006) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2006.02.006 · Cited by 15
Inayoshi, Y., Okino, Y., Miyake, K., Mizutani, A., Yamamoto-Kishikawa, J., Kinoshita, Y., Morimoto, Y., Imamura, K., Morshed, M., Kono, K., et al. (2010) · Journal of Virology · doi:10.1128/jvi.02681-09 · Cited by 14
“MoMLV prefers integration near the start sites of transcription and CpG islands that are genomic regions enriched in the rare CpG dinucleotide and commonly associated with the TATA box-less transcription start site (10, 37, 54, 61).”
BackgroundMutagenesis and Oncogenesis by Chromosomal Insertion of Gene Transfer Vectors
Baum, C. F., Kustikova, O. S., Modlich, U., Li, Z., & Fehse, B. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.ft-181 · Cited by 12
Bradley, C. M., & Craigie, R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509078102 · Cited by 14
Potential Zoonotic Infection of Porcine Endogenous Retrovirus in Xenotransplantation
Mattiuzzo, G., Takeuchi, Y., & Scobie, L. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-845-0_17 · Cited by 11
Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy
Williams, D. A., Kohn, D. B., & Thrasher, A. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.058 · Cited by 11
Polten, R., Kutle, I., Stalp, J. L., Hachenberg, J., Seyda, A., Neubert, L., Kamp, J. C., von Kaisenberg, C., Schaudien, D., Hillemanns, P., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2556714 · Cited by 12
“Compared to gammaretroviral-and lentiviral vectors that tend to integrate into transcriptional start sites 30 and active transcription units, 31 respectively, alpharetroviral vectors are associated with a more neutral integration profile, thus displaying a potentially safer approach for cell and…”
Characterization of Equine Infectious Anemia Virus Integration in the Horse Genome
Liu, Q., Wang, X., Ma, J., He, X.-J., He, X.-J., & Zhou, J.-H. (2015) · Viruses · doi:10.3390/v7062769 · Cited by 13
“Furthermore, murine leukemia virus (MLV) tends to integrate near transcription start sites (TSSs) or CpG islands [22].”
BackgroundSantoni, F. A. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1214 · Cited by 12
The chromatin backdrop of DNA replication: Lessons from genetics and genome-scale analyses
Conner, A. L., & Aladjem, M. I. (2012) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2012.01.017 · Cited by 11
“As many gene therapy vectors integrate preferentially within or close to active transcriptional domains [103, 104], enhancer elements associated with transcription regulatory elements might have a potential for deleterious mutagenesis by affecting the expression of adjacent genes.”
BackgroundChromosomal position effects on AAV-mediated gene targeting
Cornea, A. M., & Russell, D. W. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq095 · Cited by 11
“Over 50% of the target loci are within RefSeq transcription units, reflecting the MLV bias for integration near transcription start sites and within genes (44).”
BackgroundSadat, M., Dirscherl, S., Sastry, L., Dantzer, J., Pech, N. K., Griffin, S., Hawkins, T., Zhao, Y., Barese, C. N., Cross, S., et al. (2009) · Gene Therapy · doi:10.1038/gt.2009.96 · Cited by 11
Liver Cell Transformation in Chronic HBV Infection
Benhenda, S., Cougot, D., Neuveut, C., & Buendia, M. A. (2009) · Viruses · doi:10.3390/v1030630 · Cited by 12
“As previously shown for retroviruses [51,52], HBV DNA integration appears to occur frequently in actively transcribed chromosomal regions, within genes or at their immediate vicinity.”
BackgroundNguyen, T. H., & Ferry, N. (2007) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.1.1.155 · Cited by 13
Sheinberger, J., Hochberg-Laufer, H., Lavi, E., Kanter, I., Avivi-Mintz, S., Reinitz, G., Schwed-Gross, A., Aizler, Y., Varon, E., Kinor, N., et al. (2017) · Biology Methods and Protocols · doi:10.1093/biomethods/bpx004 · Cited by 11
Applications of molecular engineering in T‐cell‐based immunotherapies
McBride, D. A., Kerr, M. D., Wai, S. L., & Shah, N. J. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1557 · Cited by 12
Improved tagging strategy for protein identification in mammalian cells
Bialkowska, A. B., Zhang, X., & Reiser, J. (2005) · BMC Genomics · doi:10.1186/1471-2164-6-113 · Cited by 11
“In contrast to oncogenic retroviral vectors, lentiviral vectors can transduce dividing and non-dividing cells [23,24] and they appear to integrate preferentially into transcriptional units [14,25-27].”
Brenner, S., Ryser, M., Choi, U., Whiting‐Theobald, N., Kuhlisch, E., Linton, G. F., Kang, E. M., Lehmann, R., Rösen‐Wolff, A., Rudikoff, A. G., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.015 · Cited by 11
“Several studies have shown that retroviruses integrate nonrandomly and favor active genes [17–19,21,35–37].”
BackgroundResultInfluentialBorrenberghs, D., Zurnic, I., Wit, F. D., Acke, A., Dirix, L., Cereseto, A., Debyser, Z., & Hendrix, J. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1157 · Cited by 11
Jung, C. W., Beard, B. C., Morris, J. C., Neff, T., Beebe, K., Storer, B. E., & Kiem, H. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.04.004 · Cited by 11
Modeling Insertional Mutagenesis Using Gene Length and Expression in Murine Embryonic Stem Cells
Nord, A. S., VRANIZAN, K. M., Tingley, W. G., Zambon, A. C., Hanspers, K., Fong, L. G., Hu, Y., Bacchetti, P., Ferrin, T. E., Babbitt, P. C., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000617 · Cited by 11
“Previous studies of retroviral insertion with vectors similar to gene-trap vectors yielded contradictory results concerning the effect of geneexpression level on vector insertion [14–16]; however, retroviruses are known to integrate preferentially into transcribed genes, likely owing to the effects of chromatin struct…”
ResultWhitney, D., Shestopalov, I. A., Fincker, M., d′Anjou, M., Kral, K., Gayron, M., Pierciey, F. J., & Colvin, R. A. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101155 · Cited by 10
Retroviral Vector Technology for Gene Therapy: History, Current Landscape, and Future Prospects
Jaballah, S. A., Ali, L. M., Jehad, M. A., Akhlaq, S., Rizvi, T. A., & Mustafa, F. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169473 · Cited by 10
Use of integrase-minus lentiviral vector for transient expression.
Farazmandfar, T., Shahreza, H. K., Haghshenas, M. R., Janbabai, G., Azadeh, H., & Samaei, N. M. (2012) · PubMed Central · Cited by 14
Gene Therapy for Primary Immunodeficiencies
Fischer, A., Hacein‐Bey‐Abina, S., & Cavazzana, M. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.11.007 · Cited by 10
Safety and Efficacy of Retroviral and Lentiviral Vectors for Gene Therapy
Cesana, D., Volpin, M., Secanechia, Y. N. S., & Montini, E. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_2 · Cited by 14
Schield, D. R., Perry, B. W., Card, D. C., Pasquesi, G. I. M., Westfall, A. K., Mackessy, S. P., & Castoe, T. A. (2022) · Genome Biology and Evolution · doi:10.1093/gbe/evac116 · Cited by 10
“We estimated synonymous (dS) and nonsynonymous (dN) divergence between gametologs using the codon model in PAML (Yang 2007), and filtered pairs with dS above 2 and below 0.001.”
MethodInfluentialPlasmid DNA as a safe gene delivery vehicle for treatment of chronic inflammatory disease
Clanchy, F. I. L., & Williams, R. O. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.10.1507 · Cited by 11
“An advantage of the stable integration of a remedial gene is a reduced need for further therapeutic intervention, however there is a risk to patient safety as transcriptionally active sequences [1] , promoter regions [2] or tumour suppressor genes [3] are preferential insertion sites for virus-delivered genes.”
BackgroundSILENCE: a new forward genetic technology
Banks, D. J., & Bradley, K. A. (2006) · Nature Methods · doi:10.1038/nmeth991 · Cited by 11
Efficient Non-Viral Integration and Stable Gene Expression in Multipotent Adult Progenitor Cells
Wilber, A. C., Montoya, F. U., Hammer, L., Moriarity, B. S., Geurts, A. M., Largaespada, D. A., Verfaillie, C. M., McIvor, R. S., & Lakshmipathy, U. (2011) · Stem Cells International · doi:10.4061/2011/717069 · Cited by 10
“As a result, genome-wide analyses of the insertionsite preferences for integrating vectors are being explored in a variety of target cells and tissues [60, 61, 64, 65].”
BackgroundTalaty, P., Emery, A., Holthusen, K. A., & Everly, D. N. (2012) · Journal of Virology · doi:10.1128/jvi.00523-12 · Cited by 11
“The ERM vectors act as exontrapping vectors and preferentially integrate within regions of active transcription throughout the genome (47).”
BackgroundComputing the Statistical Significance of Overlap between Genome Annotations with iStat
Sarmashghi, S., & Bafna, V. (2019) · Cell Systems · doi:10.1016/j.cels.2019.05.006 · Cited by 10
“Wu et al. (2003) studied viral integration in the human genome finding that a large fraction of HIV-1 and MLV integrations in H9 and HeLa cells lay within the start and end of transcription of a gene.”
BackgroundUnderstanding How Genetic Mutations Collaborate with Genomic Instability in Cancer
Jilderda, L. J., Zhou, L., & Foijer, F. (2021) · Cells · doi:10.3390/cells10020342 · Cited by 12
“Viral integration sites can easily be identified by cloning the provirus and adjacent cellular DNA from the tumor DNA [67].”
BackgroundInfluentialHost Factors in Retroviral Integration and the Selection of Integration Target Sites
Craigie, R., & Bushman, F. D. (2015) · ASM Press eBooks · doi:10.1128/9781555819217.ch45 · Cited by 10
DNA pattern recognition using canonical correlation algorithm
Sarkar, B. K., & Chakraborty, C. (2015) · Journal of Biosciences · doi:10.1007/s12038-015-9555-z · Cited by 10
“For further application of CCA we have applied the method of pattern recognition in case of retroviral integration sites in the human genome (Schröder et al. 2002; Wu et al. 2003; Mitchell et al. 2004).”
MethodBiology and pathophysiology of the new human retrovirus XMRV and its association with human disease
Rusmevichientong, A., & Chow, S. A. (2010) · Immunologic Research · doi:10.1007/s12026-010-8165-y · Cited by 10
“around transcription start sites and CpG islands [ 65 , 69, 70].”
BackgroundChen, F., Wang, H., He, H., Li, S., Wu, J., Gao, Y., Liu, X., He, C., Yang, H., Chen, L., et al. (2010) · Journal of General Virology · doi:10.1099/vir.0.027680-0 · Cited by 10
“Unlike retroviruses, lentiviruses appear to have limited potential for oncogenicity (Wu et al., 2003).”
BackgroundSelf-citationMutagenesis of diploid mammalian genes by gene entrapment
Lin, Q., Donahue, S. L., Moore-Jarrett, T., Cao, S., Osipovich, A. B., & Ruley, H. E. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl728 · Cited by 12
“Flanking genomic DNA sequences were cloned by inverse PCR (49) or by ligation-mediated PCR (50) modified by the addition of a C3 spacer (Integrated DNA Technologies) to the NlaIII minus adaptor to block the amplification of fragments via adaptor primers alone.”
MethodInfluentialHe, H., Xue, J., Wang, W., Liu, L., Ye, C., Cong, Z., Kimata, J. T., Qin, C., & Zhou, P. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.135 · Cited by 10
“23 The discovery of a bias of Mo-MuLV-based vectors to integrate near transcription start sites 24,25 has prompted exploration of alternative vector types.”
Lentiviral Vector Promoter is Decisive for Aberrant Transcript Formation
Scholz, S., Fronza, R., Bartholomae, C. C., Cesana, D., Montini, E., Kalle, C. V., Gil-Fariña, I., & Schmidt, M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.162 · Cited by 10
Gallay, K., Blot, G., Chahpazoff, M., Yajjou, H., Confort, M.-P., de Boisséson, C., Roux, A. L., Luengo, C., Fiorini, F., Lavigne, M., et al. (2019) · Virology · doi:10.1016/j.virol.2019.04.002 · Cited by 10
Distribution of HIV-1 in the genomes of AIDS patients
Tsyba, L. O., Rynditch, A. V., Boeri, E., Jabbari, K., & Bernardi, G. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3436-6 · Cited by 12
Perspectives of gene therapy for primary immunodeficiencies
Chinen, J., & Puck, J. M. (2004) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/00130832-200412000-00008 · Cited by 10
Koponen, J. (2008) · Cited by 10
Hayakawa, J., Ueda, T., Lisowski, L., Hsieh, M. M., Washington, K., Phang, O., Metzger, M., Krouse, A., Donahue, R. E., Sadelain, M., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.186 · Cited by 9
“Lentiviral vector have already shown a propensity to insert into transcriptionally active genes (Schroder et al. , 2002; Wu et al. , 2003; Hematti et al. , 2004) and target cells often undergo multiple integration events, particularly at high multiplicities of infection (Woods et al. , 2003).”
Cancer therapy with genetically‐modified T cells for the treatment of melanoma
Lagisetty, K. H., & Morgan, R. A. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2636 · Cited by 9
“vectors is the risk of insertional mutagenesis as a result of their preference to integrate at transcription start sites [12].”
BackgroundOwens, J. B., Mathews, J., Davy, P. M. C., Stoytchev, I., Moisyadi, S., & Allsopp, R. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.61 · Cited by 11
Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies
Zhu, I., Piraner, D. I., & Roybal, K. T. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0962 · Cited by 10
Beyond retrovirus infection: HIV meets gene therapy
da Silva, F. H., Dalberto, T. P., & Nardi, N. B. (2006) · Genetics and Molecular Biology · doi:10.1590/s1415-47572006000200027 · Cited by 12
“Very interestingly, these reports are different for HIV and MLV, because the former integrates into active genes while the latter preferentially integrates into transcription start regions (Schröder et al., 2002; Wu et al., 2003).”
InfluentialSiapati, E. K., Bigger, B., Kashofer, K., Themis, M., Thrasher, A. J., & Bonnet, D. A. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2006.00813.x · Cited by 10
Ex vivo gene therapy cures a blistering skin disease
Featherstone, C., & Uitto, J. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.03.006 · Cited by 9
Guerrero, A. D., Moyes, J. S. E., & Cooper, L. J. N. (2014) · 癌症:英文版 · doi:10.5732/cjc.014.10100 · Cited by 10
“Likewise, lentiviral vectors prefer integration into certain genetic loci, with 57%([24]) and 69%([25]) of integration events occurring within genes, which is higher than what is expected due to random integration.”
BackgroundZheng, W., Wang, Y., Chang, T., Huang, H., & Yee, J. (2013) · Gene · doi:10.1016/j.gene.2013.01.009 · Cited by 9
“This is consistent with the finding that retrovirus preferentially integrates into active genes (Bushman et al., 2005; Wu et al., 2003).”
BackgroundMethodResultInfluentialStephen, E. B. (2006) · Frontiers in bioscience · doi:10.2741/1841 · Cited by 10
Pellaers, E., Bhat, A., Christ, F., & Debyser, Z. (2022) · Viruses · doi:10.3390/v15010032 · Cited by 8
“On the contrary, gammaretroviruses, such as murine leukemia virus (MLV), frequently integrate near transcription start sites (TSSs), CpG islands and enhancers [7,12].”
BackgroundGene therapy strategies for RAG1 deficiency: Challenges and breakthroughs
Gilioli, G., Lankester, A. C., de Kivit, S., Staal, F. J. T., & de Bruin, L. M. O. (2024) · Immunology Letters · doi:10.1016/j.imlet.2024.106931 · Cited by 9
Gene Therapy for Primary Immunodeficiencies
Martín, F., Gutiérrez-Guerrero, A., & Benabdellah, K. (2013) · InTech eBooks · doi:10.5772/55594 · Cited by 9
“Several studies have demonstrated that MLV-derived vectors integration favour transcriptionally active genes near transcription start sites (TSSs) [28-30].”
BackgroundLentiviral vectors for cutaneous RNA managing
Primo, M. N., Bak, R. O., & Mikkelsen, J. G. (2012) · Experimental Dermatology · doi:10.1111/j.1600-0625.2011.01436.x · Cited by 9
GeIST: a pipeline for mapping integrated DNA elements
LaFave, M. C., Varshney, G. K., & Burgess, S. M. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv350 · Cited by 8
Self-citationRamsubir, S., Yoshimitsu, M., & Medin, J. A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300147 · Cited by 8
Gilroy, K. L., Terry, A., Naseer, A., de Ridder, J., Allahyar, A., Wang, W., Carpenter, E. J., Mason, A. L., Wong, G. K., Cameron, E. R., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154070 · Cited by 9
“The non-randomness of murine leukemia virus (MLV) integration was first appreciated from early studies that highlighted biases towards DNaseI hypersensitive sites and transcriptional start sites [12].”
BackgroundKhorramian‐Ghahfarokhi, M., Dormiani, K., Mohammadi, A., Jafarpour, F., & Nasr‐Esfahani, M. H. (2017) · Scientific Reports · doi:10.1038/s41598-017-15648-3 · Cited by 21
Papayanni, P. G., Psatha, N., Christofi, P., Li, X., Melo, P., Volpin, M., Montini, E., Liu, M., Kaltsounis, G., Yiangou, M., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.142 · Cited by 9
“1,2 Integrating c -retroviral vectors can dys-regulate the expression of cellular genes through a variety of mechanisms, leading to genotoxicity and malignant transformation.”
Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas
Weishaupt, H., Čančer, M., Rosén, G., Holmberg, K. O., Häggqvist, S., Bunikis, I., Jiang, Y., Sreedharan, S., Gyllensten, U. B., Becher, O. J., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac158 · Cited by 8
Gene therapy: too much splice can spoil the dish
Trono, D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63066 · Cited by 9
Gammaretroviral Vector Integration Occurs Overwhelmingly Within and Near DNase Hypersensitive Sites
Liu, M., Li, C. L., Stamatoyannopoulos, G., Dorschner, M. O., Humbert, R., Stamatoyannopoulos, J. A., & Emery, D. W. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.177 · Cited by 8
Metadata
- Authors
- Wu, X., Li, Y., Crise, B., & Burgess, S. M.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Burgess, Shawn M.
- Venue
- Science
- Published
- 2003-06-13
- Volume
- 300
- Issue
- 5626
- Pages
- 1749-1751
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1637867377
- Cited by
- 1,305
- References
- 18
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 11 · 2023: 13 · 2022: 18 · 2021: 25 · 2020: 27 · 2019: 33 · 2018: 24 · 2017: 39 · 2016: 43 · 2015: 49 · 2014: 65 · 2013: 51 · 2012: 83
- FWCI
- 57.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01co12400-79-0-22)
- National Cancer Institute (N01CO12400)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Chromosomal and Genetic Variations
- Keywords
- retroviral integration, transcription start sites, murine leukemia virus, HIV-1, human genome, gene therapy
- MeSH terms
- Child, Genetic Vectors, HeLa Cells, Humans, Leukemia, Leukemia Virus, Murine, Promoter Regions, Genetic, Transcription, Genetic, Tumor Cells, Cultured, Genetic Therapy, HIV-1, Gene Expression, Genome, Human, Virus Integration, CpG Islands, Oligonucleotide Array Sequence Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.